B cells as a therapeutic target in autoimmune disease
Depleting B cells with anti-CD20 monoclonal antibodies emerges as a new therapeutic strategy in autoimmune diseases. Preliminary clinical studies suggest therapeutic benefits in patients with classic autoantibody-mediated syndromes, such as autoimmune cytopenias. Treatment responses in rheumatoid ar...
Spremljeno u:
| Izdano u: | Arthritis Res Ther |
|---|---|
| Glavni autori: | , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
BMC
2003
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC165047/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/12723978/ https://ncbi.nlm.nih.govhttps://doi.org/10.1186/ar751 |
| Oznake: |
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|